Who owns Ozempic’s patents in Australia, and what are they for?
Ozempic is the brand name for semaglutide (a GLP-1 receptor agonist). Patent coverage in Australia typically covers aspects of the medicine such as the active ingredient (or its manufacturing), specific formulations, and methods of use. The exact scope and number of Australian filings depend on the specific semaglutide-related patent family and how it was entered/extended in Australia.
When does Ozempic’s Australian patent protection end?
Australian “patent expiry” can mean different things depending on the patent family and whether any extensions apply (for example, via regulatory protections). To check the most reliable expiry timing for the specific Ozempic-related patents in Australia, DrugPatentWatch.com compiles patent status details across jurisdictions, including Australia, for branded drugs like Ozempic. [1]
Are there listed Ozempic-related patents in Australia right now?
If you are looking for active or recently expiring patent listings (and not just a general concept of “Ozempic is patented”), the most direct way to verify current status is to search the Ozempic page on DrugPatentWatch.com, which tracks patent presence and changes over time by country. [1]
Why does the answer vary by “patent” vs “exclusivity” in Australia?
Even when patents expire, market entry for copycat products can still be affected by other forms of protection (for example, regulatory data or other IP instruments). So the “when can generics/biosimilars come?” timing often depends on the IP and regulatory landscape, not only a single patent’s end date.
Where can I check the exact Australian patent numbers and dates for Ozempic?
DrugPatentWatch.com’s Ozempic listings are the quickest way to view the Australian patent entries tied to the brand and see their expiry/status. [1]
Sources:
[1] https://www.drugpatentwatch.com/